There’s no buyer’s remorse at St. Jude Medical (NYSE:STJ) when it comes to the company’s $455 million acquisition of CardioMEMS.
St. Jude CEO Dan Starks yesterday called CardioMEMS Champion HF implantable heart monitor the company’s “single most important new growth driver” and predicted the market for the product would exceed $1 billion. Sign up to get our free newsletters delivered straight to your inbox
“CardioMEMS’ technology is a perfect example of the right product in the right market at the right time and is expected to become a major new growth driver for St. Jude Medical in 2015 and beyond,” Starks told investors during the company’s 3rd quarter earnings call.
Help employers find you! Check out all the jobs and post your resume.
